References
- Rockstroh JJ, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192: 992–1002
- Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort study. Lancet 2000; 356: 1800–5
- De Luca A, Bugarini R, Cozzi Lepri A, Puoti M, Girardi E, Antinori A, et al. Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. Arch Intern Med 2002; 162: 2125–32
- Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis B or C virus infection. JAMA 2000; 283: 74–80
- Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. JAIDS 2001; 27: 426–31
- Alberti A, Clumeck N, Collins S, Gerlich W, Lundgren J, Palu G, et al. Short statement of the First European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. J Hepatol 2005; 42: 615–24
- Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585–91
- Mauss S, Klinker H, Ulmer A, Willers R, Weissbrich B, Albrecht H, et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998; 26: 16–9
- Torriano FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alpha-2a plus ribavarin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 451–9
- Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Morand P, et al. Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavarin, for chronic hepatitis C in HIV-infected patients. JAMA 2004; 292: 2839–48
- Rauch A, Egger M, Reichen J, Furrer H. Chronic hepatitis C in HIV infected patients: low eligibility and applicability of therapy with pegylated interferon-gamma plus ribavarin (letter). JAIDS 2005; 38: 238–40
- Fultz SL, Justice AC, Butt AA, Rabeneck L, Weissman S, Rodriguez-Barrados M for the VACS-3 project team. Testing, referral and treatment patterns for hepatitis C virus coinfection in a cohort of veterans with human immunodeficiency virus infection. Clin Inf Dis 2003;36:1039–46.
- Fleming CA, Craven DA, Thornton D, Tumity S, Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Inf Dis 2003; 36: 97–100
- Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in AIDS and death-rates in the EuroSIDA study: an observational study. Lancet 2003; 362: 22–9
- Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, , et al. Evidence for an increase in the death rate from liver-related disease in patients with HIV: The EuroSIDA study. AIDS 2005;19:2117–25.